Fremanezumab

• Migraine Prevention
• Chronic Migraine
• Episodic Migraine
• CGRP-Targeted Therapy

Fremanezumab (brand name Ajovy) is a fully human anti-CGRP monoclonal antibody approved for preventive treatment of migraine in adults. It is delivered as a subcutaneous injection on a flexible monthly or quarterly schedule and is intended to reduce the frequency, severity, and disability of migraine attacks rather than to treat individual headaches as they occur. Fremanezumab is appropriate for patients with frequent episodic migraine (typically defined as four to fourteen migraine days per month) or chronic migraine (15 or more headache days per month, with at least eight migraine days) who have not achieved adequate control with standard preventive medications, or who cannot tolerate them. It belongs to a class of biologics that has substantially reshaped migraine prevention since 2018.

Mechanism of Action

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide released from trigeminal sensory neurons during migraine attacks. CGRP drives meningeal vasodilation, neurogenic inflammation, and central sensitization of pain pathways within the trigeminocervical complex. The discovery that CGRP infusion provokes migraine in susceptible individuals, and that CGRP levels rise during spontaneous attacks, established it as a rational therapeutic target. Fremanezumab is a humanized IgG2 monoclonal antibody that binds CGRP itself (both alpha and beta isoforms), neutralizing the ligand before it can engage the CGRP receptor. This contrasts with erenumab, which blocks the receptor, and resembles the ligand-targeting approach of galcanezumab. Because monoclonal antibodies are large proteins, fremanezumab is cleared by intracellular catabolism (the same pathways that recycle endogenous IgG) rather than hepatic or renal pathways, which simplifies its drug interaction and dosing profile. Half-life is approximately 31 days, supporting monthly or quarterly schedules. The American Academy of Neurology guidance summarizes the role of anti-CGRP therapies in current preventive algorithms.

Clinical Use

Fremanezumab is generally reserved for patients who have failed at least two well-trialed preventives such as topiramate, propranolol, or amitriptyline, or who cannot tolerate them due to side effects, comorbidities, or interactions. Increasingly, anti-CGRP agents are used earlier in the treatment course when oral preventives are contraindicated, as in patients with renal disease, depression, weight concerns, or cardiovascular issues. Within the anti-CGRP family, fremanezumab is distinguished by the option of quarterly dosing (three injections at one visit every three months), which can improve adherence for patients who prefer fewer dosing days. Acute attacks should still be treated with a triptan such as sumatriptan, a gepant such as ubrogepant or rimegepant, or lasmiditan; fremanezumab does not abort active attacks. Patients should also continue lifestyle modifications: regular sleep, hydration, identification and management of triggers, and limitation of acute medication use to fewer than 10 days per month to avoid medication overuse headache. For broader context on neurologic care, visit our neurologic conditions page or our article on chronic stress and physical illness, since stress is a common migraine trigger.

How to Take It

Fremanezumab is administered as a 225 mg subcutaneous injection monthly, or as 675 mg (three consecutive 225 mg injections in different sites at one visit) quarterly. The pen or prefilled syringe should be removed from the refrigerator and allowed to reach room temperature for about 30 minutes before injection; do not warm it artificially with hot water or a microwave. Inject into the abdomen (avoiding a 2-inch radius around the navel), the front of the thigh, or the upper outer arm, rotating sites with each dose to reduce tissue induration. After the first in-clinic teaching session, most patients self-inject at home. The autoinjector audibly clicks at the start and end of injection; the full process takes about 5 to 10 seconds once the device is pressed firmly against the skin. If a dose is missed, administer it as soon as possible and resume the regular schedule from that date rather than the original. Many patients notice some reduction in migraine days within the first month, but a full preventive trial requires three months of consistent use before judging response.

Monitoring and Follow-Up

No routine laboratory monitoring is required. The most informative tracking tool is a headache diary documenting migraine days per month, severity (typically rated 0-10), acute medication use, and disability impact (work missed, activities cancelled). Apps and paper diaries are equally effective if used consistently. A response is generally defined as at least a 50 percent reduction in monthly migraine days; partial responders (30-50 percent reduction) may still benefit meaningfully and should not be reflexively switched. Reassess at three months and again at six months. If response is inadequate at three months despite adherence, consider switching to a different anti-CGRP agent, since cross-class response is variable. Blood pressure should be checked at routine visits, particularly for patients also using vasoactive acute therapies such as triptans or ergots. Patients with autoimmune comorbidities or other complex medical histories may benefit from periodic check-ins that include the standard panels described in our blood work overview.

Special Populations

Human pregnancy data remain limited; the long half-life means the antibody can persist for months after the last dose, so women planning pregnancy should discuss timing and discontinuation with their physician. Migraines often improve during pregnancy on their own, particularly in the second and third trimesters. Excretion into breast milk is expected to be minimal because of the antibody's molecular size and the fact that intact IgG is poorly absorbed from infant gastrointestinal tract, but firm clinical data are scarce. Safety and efficacy have not been established in patients under 18, although trials in adolescents are ongoing. Older adults included in trials tolerated treatment similarly to younger participants, with no specific dose adjustment recommended. No dose adjustment is needed for renal or hepatic impairment, since clearance does not depend on these organs. The medication is not a controlled substance and has no known abuse potential.

Practical Considerations and Combination Therapy

Anti-CGRP monoclonal antibodies are often combined with other preventive strategies, including onabotulinumtoxinA (Botox) injections for chronic migraine, oral preventives, and lifestyle approaches; combination therapy is reasonable when monotherapy provides only partial benefit. The 2024 American Headache Society position statement supports anti-CGRP therapies as appropriate first-line preventive options based on tolerability and efficacy data, removing the historical step-therapy requirement of failing two oral preventives in many practices. Cost and insurance coverage remain practical barriers; patient assistance programs from the manufacturer can be useful for uninsured or underinsured patients. Refrigeration during travel is straightforward with cold packs and an insulated bag for short trips; for longer journeys, the autoinjector can stay at room temperature for up to seven days. Patients should plan ahead for refills, as specialty pharmacy delivery sometimes requires several days of lead time. Tracking response is critical because subjective recall of headache frequency is unreliable; structured tools such as the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test (HIT-6), or daily diaries identify true responders. For patients on opioids or barbiturate-containing combination products for migraine (largely discouraged in modern practice), starting a CGRP preventive can be the first step in a structured taper from these agents. Stress management, regular sleep, hydration, and identification of dietary or environmental triggers remain foundational, as covered in our article on recognizing burnout and exhaustion. Hormonal triggers, including menstrual migraine, often persist on anti-CGRP therapy and may warrant additional targeted strategies. Coexisting medication overuse headache should be addressed concurrently because preventive efficacy is reduced when acute medications are used more than 10-15 days per month.

When to Contact Your Doctor

Seek immediate care for signs of a severe allergic reaction: hives, swelling of the face or tongue, wheezing, or difficulty breathing, which can occur hours to days after injection because of the slow absorption of subcutaneous biologics. Persistent injection-site reactions with spreading redness, warmth, or fever may indicate cellulitis or local infection. Constipation severe enough to alter daily function, new or worsening hypertension, or unusual changes in headache pattern (sudden severe headache, new neurologic symptoms such as weakness, numbness, vision loss, or speech difficulty) deserve prompt evaluation, as the latter may indicate stroke or other serious processes that require urgent imaging. Anti-CGRP therapies have been associated with new-onset hypertension and Raynaud-like symptoms in postmarketing surveillance, so report new finger or toe color changes triggered by cold.

If migraine is interfering with work, family time, sleep, or quality of life, contact us or schedule a visit to discuss whether fremanezumab fits into your preventive plan.